BiotechTube

Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia

Trial Timeline

Sep 24, 2012 → Jun 3, 2013

NCT ID
NCT01789606

About Ibuprofen 600 mg Immediate Release/Extended Release Caplet

Ibuprofen 600 mg Immediate Release/Extended Release Caplet is a phase 3 stage product being developed by Pfizer for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT01789606. Target conditions include Analgesia.

What happened to similar drugs?

5 of 9 similar drugs in Analgesia were approved

Approved (5) Terminated (0) Active (4)
✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
🔄HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
🔄HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
✅HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
✅Bupivacaine HClHeron TherapeuticsApproved
🔄HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03722238Phase 3Terminated
NCT01789606Phase 3Completed

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
42
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
31
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
50
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
42
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
27
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
29
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
40
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
30
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
33
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
25
Bupivacaine HClHeron TherapeuticsApproved
33
HTX-011 + PlaceboHeron TherapeuticsPhase 2
25
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
30
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
33
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
17